Marketresearchnews

Monday, 18 March 2019

Spinal Needles Market size and Key Trends in terms of volume and value 2018

Spinal needle are the medical devices generally used for the diagnostic or therapeutic purposes. These needles are inserted into spinal canal for the collection of cerebrospinal fluid (CSF) for diagnostic testing or drug administration for the treatment of diseases. The sample collected is mainly used for diagnosing diseases related to central nervous system. The global spinal needles market is chiefly driven by increasing prevalence of different brain and spinal diseases. Increasing prevalence of neurological disorders, generic population and increasing number of patients suffering from neurodegenerative disorders like Alzheimer’s and Parkinson’s disease are major driving factors for the market. Beside this, increasing awareness about diseases, increasing healthcare expenditure of people and increasing governmental support for the research and development also contribute for the growth of the market. Development of alternative diagnostic tests and misconception about spinal needles in people hampers the growth of market.

The global spinal needle market is expected to grow at a CAGR of 6.8% during the forecasted period 2017-2023.

Study objectives global spinal needles market

Detailed information about the factors affecting the growth of the global spinal needles
Detailed analysis of parent market with respect to all the possible segmentation of the market.
Detailed analysis of emerging key players for the market with their effective strategies.
Detailed Information about the present and forecasted market and factors that influences the market on global scale.
To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global spinal needles market.
Analysis of the market of the different factors like- Price Analysis, Supply Chain Analysis, Porters Five Force Analysis etc.
Detailed information on the possible segments and sub segments of the market. And regional analysis of the market.
Insights on the major countries in which this industry is blooming and to also identify the regions that are still untapped
Detailed information on trends and the opportunities in various regions.

Key players for global spinal needles market

Boston Scientific (US), B. Braun (Germany), Medline Industries (US), Sarstedt (UK), BD (US), Smiths Medical (US), Halyard Health (US), Exel International (US), MYCO Medical (US), Wallach Surgical (US), Medtronic (UK), Novo Nordisk (Denmark), Stryker Corporation (US), Argon Medical Devices, Inc (Netherland), Cook Medical (US)

Segmentation

Global spinal needle market is segmented on the basis of type, application and end users. On the basis of type, the market is segmented into atraumatic needle tips, directional spinal needles, pencil-point needles and others. On the basis of size, the market is segmented into 24G, 25G, 27G and other. On the basis of application, the market is segmented into diagnostic and therapeutic. And on the basis of end users, they are segmented into hospitals, clinics and other.

Intended Audience

Spinal needles manufacturers
Spinal needles suppliers
Research and Development (R&D) companies
Independent research laboratories
Market research and consulting service providers
Medical research laboratories
Academic medical institutes and universities

Regional analysis

Global spinal needle market is dominated by America. America’s spinal needle market is majorly driven by increasing number of spinal surgeries, increasing prevalence of different neurological disease and increasing awareness among the people. Well-developed healthcare sectors and increasing healthcare expenditure with rising prevalence of diseases has driven the Europe spinal needle market to acquire the second position. Asia Pacific region is expecting a faster growth for the market during forecasted period. Presence of huge patient population suffering from different infectious diseases is the major driving factor for the market in Asia Pacific region.

Browse for more details @ https://www.marketresearchfuture.com/reports/spinal-needles-market-1216

The report for global spinal needles market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Vocal Cord Paralysis Market size and Key Trends in terms of volume and value 2018

Market Synopsis

The global vocal cord paralysis market is expected to exhibit a 3.8% CAGR from 2018 to 2023 (forecast period), as per the latest report by Market Research Future (MRFR) owing to prevalence of brain disorders. Vocal cord paralysis is a medical condition in which nerves leading to vocal cords are damaged causing dysphonia. It is also known as vocal fold paresis.

Growing cases of neck, head, and laryngeal cancers is one of the major factors expected to bolster market demand over the forecast period. Moreover, surgeries carry the highest risk of causing vocal cord paralysis. Technological advances in the medical sector such as endoscopy, laryngoscopy, and others can be used in rapid diagnosis of the condition and thrust the market growth to new heights. Increased healthcare expenditure of several countries can facilitate the market demand till 2023. Favorable medical reimbursement schemes provided in various economies offer the vocal cord paralysis market scope to expand in the forthcoming years.

Report Overview

The report provides a comprehensive overview of the market complete with statistical graphs to support the forecasted figures. Our analysts make insightful predictions regarding the scope of the market and its future prospects. MRFR’s report includes a thorough analysis of the global vocal cord paralysis market segmented on the basis of type, treatment, and region. Numerous growth strategies undertaken by companies as well as the latest trends driving the market are outlined in the report. The market share of all prominent players and their current position is discussed in minute detail. It analyzes new revenue sources for players and emphasizes on the various strategies implemented by players.

Segment Overview

By type, the market is divided into unilateral and bilateral. Treatment options in the vocal cord paralysis market voice therapy and surgery. The surgery treatment segment is further divided into structural implants, tracheotomy, bulk injection (phonosurgery), and vocal cord repositioning. The segments covered in the vocal cord paralysis market report are analyzed with respect to four regions namely – Americas, Middle East & Africa (MEA), Asia Pacific (APAC), and Europe. The report discusses in detail the various players residing in these regions and their respective strategies to climb up the market standings.

Competitive Landscape

Key players in the vocal cord paralysis market include Cytophil, Inc. (U.S.), Teleflex Incorporated (U.S.), Medtronic Plc (U.S.), Olympus Corporation (Japan), Stryker Corporation (U.S.), FUJIFILM Holdings Corporation (Japan), LifeCell Corporation (U.S.), Therapy Solutions Inc. (U.S.), KARL STORZ GmbH & Co. KG (Germany), and Smiths Group Plc (U.K.).

The report offers a comprehensive analysis on the profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, expansion techniques, and latest R&D initiatives are discussed in minute detail.

Research Methodology

At MRFR, our research analysts conduct a thorough objective analysis of the market while creating market reports by adhering to a rigorous set of standards which allow a truly comprehensive view of the market. Use of primary research strategies such as interviews with chief executive officers and top management professionals in hospital chains have culminated in highly relevant data. Secondary research entails a thorough analysis of past and present trends presented in a forward-looking manner.

In addition, market size estimation and validation of trends are conducted with both top-down & bottom-up approaches to obtain data from the value and supply chain. The balanced number of buyers and suppliers will result in a negligible demand-supply gap. Credible resources are accessed and verified by analysts to understand the nuances of market factors with consistency. Strong analytical tools are used to ascertain accurate analysis of very relevant parameters in an effort to provide clients with a conclusive and dependable view of the future.

Browse for more details @ https://www.marketresearchfuture.com/reports/vocal-cord-paralysis-market-5079

About US:

Cerebral Palsy Market Analysis, Study and Pipeline Review 2018

Market Scenario

The global cerebral palsy market is expected to grow significantly over the forecast period. Cerebral palsy (CP) refers to a group of neurological conditions that affect muscle movement and coordination. CP can be caused by damage that occurs to the immature developing brain of an infant. In addition to this, other possible causes of CP include asphyxia neonatorum, bleeding into the brain, brain infections, and severe jaundice in the infants. Cerebral palsy is the most common form of childhood disability. According to the Cerebral Palsy Guidance, around 10,000 babies are born each year in the US with cerebral palsy.

The global cerebral palsy market is driving owing to the growing prevalence of cerebral palsy coupled with increasing awareness about the condition. Moreover, the growing adoptions of medications for controlling the symptoms of the cerebral palsy are anticipated to propel the market growth. Additionally, increasing expenditure for the healthcare sector in developed economies and increasing insurance coverage contribute to the growth of the market.

Despite the drivers, side effects associated with medications and high treatment cost and lack of awareness in some developing regions may hamper the market growth during the assessment period.

Segmentation

The global cerebral palsy market has been segmented into type, diagnosis, and treatment.

The market, on the basis of type, has been segmented into spastic cerebral palsy, dyskinetic cerebral palsy, hypotonic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy.

The market, by diagnosis, has been segmented into imaging tests and others. The imaging tests have been further segmented into magnetic resonance imaging (MRI), cranial ultrasound, computed tomography, and electroencephalogram.

The market, by treatment, has been segmented into therapy, medication, surgery, and others. The therapy segment has been segmented into nutrition therapy, hyperbaric oxygen therapy, occupational therapy, physical therapy, stem cell therapy, and others. The medication segment has been segmented into anti-convulsant drugs, muscle relaxants, anti-depressant drugs, anti-inflammatory drugs, and others. Further, the surgery segment has been segmented into orthopedic surgery and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The cerebral palsy market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European cerebral palsy market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The cerebral palsy market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cerebral palsy market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players

Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc., Medtronic, Meridigen Biotech Co., Ltd., GW Pharmaceuticals Plc, and Cell Cure Neurosciences Ltd. are some of the key players in the global cerebral palsy market.

Browse for more details @ https://www.marketresearchfuture.com/reports/cerebral-palsy-market-6334

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global cerebral palsy market owing to a well-developed healthcare sector, rising prevalence of cerebral palsy and growing healthcare expenditure. Additionally, favorable reimbursement scenario in this region and a relatively large number of research and development (R&D) activities contributes to the growth of the market.

Europe is expected to hold the second largest position in the global cerebral palsy market. The market growth in this region is attributed to the growing prevalence of cerebral palsy, availability of funds for research, and increasing healthcare expenditure. According to the data stated by the National Institute for Health and Care Excellence (NICE) in 2017, in the UK, it is estimated that 1 in 400 babies are born with cerebral palsy. It also stated that approximately 1,800 children diagnosed with CP each year.

The cerebral palsy market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and Rest of Asia-Pacific. Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, rising prevalence of cerebral palsy and increasing government funding for the healthcare sector.

On the other hand, the Middle East & Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector and growing government initiatives for the healthcare sector.

About US:

Autoimmune Disease Treatment Market size and Key Trends in terms of volume and value 2018

An autoimmune disease is a condition in which body's immune system destroys its own body tissue. There are more than 80 different type of autoimmune disorders but the most common are multiple sclerosis, IBD, diabetes, rheumatoid arthritis, psoriasis, and others. Autoimmune disease may result in abnormal growth of an organ, the destruction of body tissue, and changes in organ function

According to the National Institutes of Health (NIH), around 23.5 million Americans are suffering from autoimmune disease. NIH has also estimated that the annual direct health care costs for autoimmune disease are near to the USD 100 billion. Whereas for cancers, and heart & strokes, the cost is around USD 57 billion, and USD 200 billion respectively.

Notably, growing public awareness, and the increasing prevalence of autoimmune diseases, and other related complications are the key factors driving the autoimmune disease treatment market. Government and other different private associations have started educating people about diseases through seminars, and conferences. For instance, the American Autoimmune Related Diseases Association in collaboration with the National Coalition of Autoimmune Patient Groups conducts a program, named Autoimmune Research Network (ARNet). Through this research network, researchers empowers patients by supporting their participation in research on autoimmune diseases by gathering patient information. This information is majorly helpful during clinical trials.

Various other factors such as technological advancements, unmet medical needs, increasing government assistance, rising prevalence of co-existing disorders, improving regulatory framework, improving funding and reimbursement policies, and increasing adoption rate, are continuously contributing towards the growth of the global autoimmune disease treatment market.

Despite these drivers, there are some issues associated with autoimmune disease treatment market. High cost of treatment, presence of misbranded drugs, side-effects of treatment, and poor healthcare system in low or middle-income countries, may hamper the growth of the market.

It is estimated that the autoimmune disease treatment market is expected to grow at a CAGR 11.2% during the forecast period of 2017-2023.

Intended Audience

Pharmaceutical Companies
Research and Development (R&D) Companies
Diagnostic Laboratories
Government Research Institute
Academic Institutes and Universities

Segmentation

The global autoimmune disease treatment market is segmented on the basis of disease type, diagnosis, therapeutic products, and distribution channels.

On the basis of the disease type, the market is classified as localized, and systemic. The localized segment is further classified into multiple sclerosis, inflammatory bowel disease, diabetes, and other. The systemic segment is further classified into rheumatoid arthritis, psoriasis, lupus, and others.

On the basis of the diagnosis, the market is classified as ELISA, dot blot, line blot, agglutination, double immune diffusion, western blotting, multiplex immunoassay, and others.

On the basis of the therapeutic products, the market is classified as drugs, and therapeutic and monitoring equipment. The drugs segment is further segmented into biologics, immunosuppressant, anti-inflammatory drugs, corticosteroids, and non-steroidal anti-inflammatory drugs.

On the basis of the distribution channel, the market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.

Regional Analysis

The Americas dominate the autoimmune disease treatment market owing to the rising cases of autoimmune diseases, and high healthcare expenditure. As per the data suggested by Centers for Disease Control and Prevention in 2015, the total healthcare expenditure in the U.S. was reported to be USD 3.2 trillion, whereas, hospital care accounted for a share of 32.3%.

Europe holds the second position in the autoimmune disease treatment market. It is expected that the financial support provided by the government bodies for research & development and amendments in reimbursement policies in the healthcare is likely to drive the European market

Owing to a huge patient pool and developing healthcare technology, Asia Pacific is the fastest growing autoimmune disease treatment market. Healthcare expenditure is also found to be escalating in various Asia Pacific countries. The Australian Institute of Health and Welfare suggested that in the year 2015-2016, the total healthcare expenditure was USD 170.4 billion, which is around 3.6% higher than the expenditure during 2014-2015.

The Middle East & Africa holds the lowest market due to poor medical facilities, and lack of technical knowledge.

Browse for more details @ https://www.marketresearchfuture.com/reports/autoimmune-disease-treatment-market-5586

Key players

Some of key the players in the global autoimmune disease treatment market are Abbott Laboratories, Amgen Inc., Genentech Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bio-Rad, Chugai Pharmaceutical Co. Ltd., Danaher, Elan Corporation Plc, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, HYCOR Biomedical, Johnson & Johnson Inc., Merck & Co. Inc., Siemens, Squibb Company, Thermo Fisher Scientific, and others.

About US:

Hip Tendinitis Market size and Key Trends in terms of volume and value 2018

Market Scenario:

Hip tendonitis refer to a condition in which single or many tendons connects various muscles to the hip bone, get damaged. The hip and pelvis joints supports the body weight in an upright position. The muscles present in this region are more bulky and strong, however, tendons are prone to damage with increasing age and changing lifestyle. During the last decade, the lifestyle of the people across the globe has changed dramatically. Increasing incident of sports injuries, rising geriatric population, increasing patients population suffering from rheumatoid arthritis & diabetes, and adoption of sedentary lifestyle have led to increase the prevalence of hip tendonitis, which significantly drives the market growth. According to the US centers for diseases control, over 10% of kids and teen participating in the sports suffer from minor or major types of injuries. Additionally, increasing government support for research & development of different drugs, changing lifestyle and lack of exercise have fuelled the market growth. However, long approval time for drugs and lack of precise treatment may slow the growth of the market.

The global hip tendinitis market is expected to grow at a CAGR of 4.55% during forecast period 2017-2023.

Intended Audience

Pharmaceutical companies
Biotechnological institutes
Government and Private Laboratories
Research and Development (R&D) Companies
Medical Research Laboratories
Market Research and Consulting Service Providers

Segmentation

The global hip tendinitis market is segmented on the basis of types, treatment, and end users.

On the basis of types, the market is segmented into internal snapping hip, external snapping hip, and intra-articular snapping hip.

On the basis of treatment, the market is segmented into diagnosis and therapy. The diagnosis is further segmented into physical exam, imaging tests, and others. Imaging test is further segmented into ultrasound, magnetic resonance imaging (MRI) scans, and others. The therapy is segmented into pharmacological, non-pharmacological, shock wave or surgery, medical devices, and others. The pharmacological therapy is further segmented into OTC drugs, corticosteroids injections, platelet-rich plasma (PRP), and others. The medical devices are further segmented into mechanical band, support tape, pre-cut strips, continuous rolls, and others.

On the basis of end users, the market is segmented into hospitals & clinics, medical research centers, academic institutes, and others.

Regional Analysis

The global hip tendinitis market is dominated by America owing to the presence of huge geriatric population and continuous increasing number of diabetic patients. As per the report published by the population reference bureau, in 2015, the number of Americans ageing over 65 were 46 million, which is expected to reach over 98 million by 2060. Furthermore, increasing number of patients suffering form rheumatoid arthritis, changing lifestyle, and huge healthcare spending have boosted the growth of the market in America. According to the American Diabetes Association, over 30.3 million Americans population were suffering from diabetes in 2015. Additionally, increasing awareness among the people regarding different types of diseases and increasing government support is likely to contribute to the growth of the market during the review period 2017-2023.

Europe accounts for the second largest hip tendinitis market, which is followed by Asia Pacific. According to the Eurostat, in 2016, 19.2% of total European population were over age 65 years. Increasing geriatric population and adoption of sports by the people may drive the market growth. Moreover, availability of funds for research, and government support for research & development are expected to fuel the market growth.

Asia Pacific is the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, and the presence of huge opportunity in the market. On the other hand, the Middle East & Africa holds the least share in the global hip tendinitis market due to presence of poor economy, especially, in African region. The Middle East holds the major share of the Middle East & African market owing to the well-developed healthcare sector and huge healthcare expenditure.

Browse for more details @ https://www.marketresearchfuture.com/reports/hip-tendinitis-market-4764

Key players for global hip tendinitis market

Some of the key players in the global hip tendinitis market are Almatica Pharma, Inc (U.S.), AstraZeneca (U.K.), Bayer AG (Germany), Boehringer Ingelheim Pharmaceuticals, Inc (Germany), Merck & Co., Inc (U.S.), Pfizer (U.S.), Abbott (U.S.), GlaxoSmithKline plc (U.K.), Teva Pharmaceuticals (Taiwan), Lupin Pharmaceuticals, Inc. (India), Geri-Care Pharmaceuticals. (U.S.), and Perrigo Company (U.S),

About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com

Cardiovascular Needle Market size and Key Trends in terms of volume and value 2018

Market Scenario

Cardiovascular needles are used as a part of various heart and vascular mediations to close the surgical wound. Various surgeries such as cardiovascular surgeries, open heart surgery, cardiac valve procedures, heart transplant, coronary artery bypass graft surgery, and many more surgeries need surgical needles. Rising number of a patient having cardiovascular disease, diabetes, obesity and increasing aging population is driving the cardiovascular needles market.

According to the World Health Organization (WHO), in 2015, around 17.7 million people died from cardiovascular diseases, which represents 31% of all global deaths. Of these deaths, around 7.4 million were due to coronary heart disease and 6.7 million were due to stroke.

According to the World Health Organization (WHO) in 2015, around 1.6 million deaths were directly caused by diabetes and in 2014, 8.5% of adults aged 18 years and older had diabetes. Thus, rising prevalence of chronic diseases is majorly driving the global cardiovascular market.

Various factors are adding fuel to the growth of the global cardiovascular needle market, such as unhealthy diet, low physical activities, etc. According to a research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the market.

Moreover, advancing technology in the medical devices is adding fuel to the growth of the market. Furthermore, increasing government support in the developing countries drive the market growth.

However, increasing use of surgical staples instead of needles and suture can deter the demand for cardiovascular needles.

The global cardiovascular needle market is expected to grow at a CAGR of 7.2% during the forecast period 2017-2023.

Intended Audience

Cardiovascular needle manufacturers
Cardiovascular needle suppliers
Research and Development (R&D) Companies
Government Research Laboratories
Independent Research Laboratories
Government and Independent Regulatory Authorities
Market Research and Consulting Service Providers
Medical Research Laboratories
Academic Medical Institutes and Universities

Segmentations

The global cardiovascular needle market is segmented on the basis of types, by application, by usage, and by the end user.

On the basis of the type, it is segmented into round bodied needles and cutting needles. Furthermore, round-bodied needles segmented into taper point needles and blunt point needles. Also, cutting needles segmented into conventional cutting needles and reverse cutting needles.

On the basis of the application, it is segmented into open heart surgery, cardiac valve procedures, coronary artery bypass graft surgery, heart transplant, and others.

On the basis of the usage, it is segmented into single use and multiple uses.

On the basis of the end user, it is segmented into hospitals, clinics, ambulatory surgical centers, and others.

Regional Analysis

The Americas dominate the global cardiovascular needle market owing to the rising prevalence of diabetes, obesity, and cardiovascular diseases. Furthermore increasing government support for research & development have fuelled the growth of the market in this region. According to the American Heart Association, in 2017, cardiovascular disease listed as the underlying cause of death which is likely to account for nearly 801,000 deaths in the US by the end of this year. It further estimated that about 2,200 Americans die of cardiovascular disease each day.

Europe holds the second position in the global cardiovascular needle market owing to the presence of major players. Although companies within this region are also involved in export to the developing countries which leads the market of Europe.

The Asia Pacific is the fastest growing Cardiovascular Needle market owing to the high presence of a patient with cardiovascular disease. Furthermore, the government of this region is looking forward to better the quality of needles, which increases the demand for cardiovascular needle market in this region.

On the other hand, in the Middle East and Africa hold the least market due to low research and development activities and poor healthcare infrastructure.

Browse for more details @ https://www.marketresearchfuture.com/reports/cardiovascular-needle-market-1234

Key Players

Some of the key the players in the market are Becton, Dickinson, and Company (US), B. Braun Melsungen AG (Germany), Sheffield Ltd. (UK), CP Medical, Inc. (the US), Ethicon Inc. (US), KLS Martin Group (US), Sklar Surgical Instruments (US), Rumex International Corporation Ltd. (US), Scanlan International Inc. (US), Teleflex Incorporated (US), Medline Industries, Inc. (US), Surgins surgical Ltd. (UK), Surtex Instruments Ltd. (UK), Cardivon Surgical Inc. (China), Symmetry Surgical Inc. (US), Delacroix-Chevalier (France), Wexler Surgical (US), Quality Needles Pvt. Ltd. (India), FSSB surgical needles GmbH (Germany)

Thursday, 14 March 2019

Male Breast Cancer Market Trends and Drivers Analysis 2018 To 2023

The global male breast cancer market is expected to grow slowly at a CAGR of ~ 3.6% during the forecast period from 2018 to 2023. Male breast cancer is caused when the breast tissues of males start growing out of control and become cancerous.

Numerous factors such as increasing obese population and growing geriatric population are expected to drive the growth of the market. For instance, in July 2017, the Bristol-Myers Squibb Company announced a broad clinical collaboration with Clovis Oncology for evaluating the combination of cancer drugs Nivolumab and Rucaparib in Phase 2 and Phase 3 clinical trials in multiple tumor types.

Moreover, favorable healthcare expenditures boost the growth of the market. However, lack of knowledge and the high cost of treatments may hamper the market growth during the assessment period.

Segmentation

The global male breast cancer market has been segmented into type, diagnosis, and treatment.

The market, on the basis of type, has been segmented into, ductal carcinoma in situ, Paget’s disease of the nipple, inflammatory breast cancer, and infiltrating ductal carcinoma.

The market, by diagnosis, has been segmented into, mammography, biopsy, PET scan, CT scan, MRI scan, and other tests. On the basis of diagnosis, biopsy is anticipated to record the largest growth owing to its accuracy of diagnosing the disease. It is also expected to be the fastest growing segment.

By diagnosis, biopsy is further segmented into, fine needle aspiration biopsy, core biopsy, and excisional biopsy.

The market, by treatment, has been segmented into, local treatments and systemic treatments.

By treatment, local treatments are further segment into, surgery and radiation therapy.

Surgery is further segmented into, mastectomy, breast-conserving surgery, and lymph nodes biopsy.

By treatment, systemic treatments are further segmented into, chemotherapy, hormone therapy, and targeted therapy.

Chemotherapy is further segmented into, adjuvant therapy and neoadjuvant therapy.

Hormone therapy is further segmented into, using drugs and orchiectomy (castration).

Targeted therapy is further segmented into, for HER2 positive breast cancer, for hormone receptor-positive breast cancer, and for cancer with BRCA mutations.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The male breast cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European male breast cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The male breast cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The male breast cancer market in the Middle East and Africa has been segmented into the Middle East and Africa.

Key players

Achieve Life Sciences, Inc., Pfizer, Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Sanofi, Novartis AG, BioNumerik Pharmaceuticals Inc., Seattle Genetics, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca, Accord Healthcare, and Bayer AG are some of the key players in the global male breast cancer market.

Read Comprehensive Overview of Report @ https://www.marketresearchfuture.com/reports/male-breast-cancer-market-6505